Breaks Categories: Analyst Alerts

WednesdayApr 29, 2020 12:34 pm

NetworkNewsBreaks – AVROBIO Inc. (NASDAQ: AVRO) Featured in Mizuho Securities Research Report

AVROBIO Inc. (NASDAQ: AVRO) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We hosted a doc call last week with a leading expert in the field of stem cell and gene therapy to discuss AVRO's ex-vivo gene therapy approach, including use of conditioning regimen. Bottom line: AVRO's ex-vivo approach may hold important advantages in the context of lysosomal storage disorders, including a more "systemic effect" compared to AAV, and the potential to circumvent antibody formation. Busulfan conditioning is very tolerable, avoiding important side effects of allogenic transplantation such as GVHD, and…

Continue Reading

TuesdayApr 28, 2020 12:26 pm

NetworkNewsBreaks – ViewRay Inc. (NASDAQ: VRAY) Featured in Mizuho Securities Research Report

ViewRay Inc. (NASDAQ: VRAY) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We are dropping coverage of ViewRay Inc. due to a reallocation of resources. Our final rating is Buy, and our final price target is $7.00. Our former estimates, price targets, and ratings should no longer be relied upon going forward.” To request access to the full report, visit http://nnw.fm/SaZ9d About ViewRay Inc. ViewRay® Inc. designs, manufactures, and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to…

Continue Reading

TuesdayApr 28, 2020 12:21 pm

NetworkNewsBreaks – Zogenix Inc. (NASDAQ: ZGNX) Featured in Mizuho Securities Research Report

Zogenix Inc. (NASDAQ: ZGNX) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Zogenix hosted a KOL event on 4/22. The most important data point in our view was the updated long-term data from FINTEPLA in Dravet syndrome, which reinforces the strong profile of FINTEPLA in this indication and the potential for the drug to become standard of care. Clinical data in a new indication (Sunflower syndrome) was also presented, with early signal observed in a handful of patients. However, we believe more clinical data will be needed before this indication can…

Continue Reading

TuesdayApr 28, 2020 12:16 pm

NetworkNewsBreaks – Aerie Pharmaceuticals Inc. (NASDAQ: AERI) Featured in Mizuho Securities Research Report

Aerie Pharmaceuticals Inc. (NASDAQ: AERI) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We applied a weighted average valuation (DCF and EV/Sales) to derive our $34 PT. Our assumptions include: Rhopressa: U.S. peak-sales of $162 mil in 2025. Rocklatan: U.S. peak-sales of $331 mil in 2025. DCF Assumptions: Terminal value of 5x 2028 FCF and a 13% discount rate to derive a $40 PT. EV/Sales Assumptions: 3.8x multiple of 2028 sales, discounted at 13% to derive a $27 PT. In our bull case scenario, we assume greater than anticipated market share…

Continue Reading

TuesdayApr 28, 2020 12:11 pm

NetworkNewsBreaks – Xeris Pharmaceuticals Inc. (NASDAQ: XERS) Featured in Mizuho Securities Research Report

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Recent prescription trends of the overall glucagon market as well as Gvoke prefilled syringe turned more negative than our expectation due to COVID-19. This prompted us to do scenario analyses based on current trends. As a result, we are lowering our 2020 and 2021 revenue estimates from $11.9 MM and $60.9 MM to $5.4 MM and $41.1MM, respectively. However, we believe the long-term, ready-to-inject glucagon market opportunity has not changed, along with Xeris' relative competitive standing. As such,…

Continue Reading

WednesdayApr 22, 2020 12:58 pm

NetworkNewsBreaks – Adaptimmune Therapeutics Inc. (NASDAQ: ADAP) Featured in Mizuho Securities Research Report

Adaptimmune Therapeutics Inc. (NASDAQ: ADAP) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We initiate shares of ADAP with a Neutral and a $3 price target. We see the efforts to develop a TCR-based treatment for solid tumors as having reached an important milestone of human data and a path forward for lead programs, but the valuation, in our view, reflects the near term value of ADAP's technology.” To request access to the full report, visit http://nnw.fm/SaZ9d About Adaptimmune Therapeutics Inc. Adaptimmune is a clinical-stage biopharmaceutical company focused on the development…

Continue Reading

WednesdayApr 22, 2020 12:52 pm

NetworkNewsBreaks – Autolus Therapeutics plc (NASDAQ: AUTL) Featured in Mizuho Securities Research Report

Autolus Therapeutics plc (NASDAQ: AUTL) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We initiate coverage of AUTL with a BUY rating and an $18 PT. AUTL's technology has shown the ability to deliver CAR-T with an enhanced safety profile, which we see as a unique and differentiating feature relative to commercially available products. We like the flexibility of the technology, the proximity to value-generating inflection points for the pipeline, and strong cash position. Our $18 PT is based a discounted NPV on revenue through 2029.” To request access to the…

Continue Reading

FridayApr 17, 2020 1:20 pm

NetworkNewsBreaks – Evolus Inc. (NASDAQ: EOLS) Featured in Mizuho Securities Research Report

Evolus Inc. (NASDAQ: EOLS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Evolus announced a business update after the close as the aesthetics-focused company adjusts its cost structure and commercialization strategy in the face of the COVID-19 pandemic. With the majority of US aesthetics practices now closed or only seeing urgent cases, and the economic impact of the pandemic expected to significantly impact discretionary spending for several months, the company is reducing its headcount by >40%, temporarily reducing executive salaries and Board of Director fees, and delaying the European launch of…

Continue Reading

FridayApr 17, 2020 1:19 pm

NetworkNewsBreaks – Xeris Pharmaceuticals Inc. (NASDAQ: XERS) Featured in Mizuho Securities Research Report

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We applied a weighted average valuation methodology (DCF+EV/Sales) to derive our $18PT. Our assumptions include: Launch of the glucagon rescue pen in the U.S. market in 4Q19, with peak-sales of $399 mil in 2029. DCF Assumptions: Terminal value of 4.0x 2029 FCF and 13% discount rate to derive a $20 PT. EV/Sales Assumptions: 4.0x multiple of 2025 sales, discounted at 13% to derive a $16 PT. Additional pipeline indications represent upside to our current price target.” To request…

Continue Reading

FridayApr 17, 2020 12:04 pm

NetworkNewsBreaks – Aerie Pharmaceuticals Inc. (NASDAQ: AERI) Featured in Mizuho Securities Research Report

Aerie Pharmaceuticals Inc. (NASDAQ: AERI) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We applied a weighted average valuation (DCF and EV/Sales) to derive our $34 PT. Our assumptions include: Rhopressa: U.S. peak-sales of $162 mil in 2025. Rocklatan: U.S. peak-sales of $331 mil in 2025. DCF Assumptions: Terminal value of 5x 2028 FCF and a 13% discount rate to derive a $40 PT. EV/Sales Assumptions: 3.8x multiple of 2028 sales, discounted at 13% to derive a $27 PT. In our bull case scenario, we assume greater than anticipated market share…

Continue Reading